TAO Synergies Inc. (TAOX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 14, 2025, covering events occurring on October 13, 2025. TAO Synergies Inc., an emerging growth company incorporated in Delaware, announced a private placement financing, the termination of a key consulting agreement, and a board appointment.
Key Financial Metrics and Transaction Details
- Financing Proceeds: Expected aggregate gross proceeds of $11.0 million from the sale of Series E Convertible Preferred Stock.
- Security Structure: 11,000 shares of Series E Preferred Stock (stated value $1,000/share) initially convertible into up to 1,375,000 shares of Common Stock at $8.00 per share.
- Warrants: Investors received warrants to purchase up to 1,375,000 shares of Common Stock at an exercise price of $8.00 per share, expiring in five years.
- Dividends: Preferred Stock accrues 7% per annum compounded quarterly (payable in cash), increasing to 15% per annum upon a "Triggering Event."
- Transaction Costs: Placement agent fees include 8.0% of gross proceeds plus a $10,000 due diligence fee, plus warrants equal to 4.0% of the initial conversion shares.
- Use of Proceeds: General corporate purposes and working capital.
- Liquidity and Debt: The filing does not provide current cash balances, total debt, or liquidity ratios. The transaction is intended to bolster working capital.
Material Changes and Corporate Actions
- Capital Structure Change: The issuance of Series E Preferred Stock and associated warrants represents a significant dilution event, with potential issuance of up to 2,750,000 shares of Common Stock (conversion shares plus warrant shares) upon full exercise/conversion.
- Consulting Termination: The Company terminated its consulting agreement with Dr. Daniel L. Alkon, effective October 3, 2025. Dr. Alkon previously served on the Bryostatin Development Committee. The Company remains obligated to pay incentive fees if certain Bryostatin asset transactions occur within one year of termination.
- Board Appointment: Bruce Bernstein was appointed Vice-Chairman of the Board on October 1, 2025.
Guidance, Risks, and Contingencies
- Stockholder Approval: The Company must seek stockholder approval for the issuance of shares exceeding 19.99% of outstanding Common Stock by December 31, 2025, to comply with Nasdaq listing standards.
- Registration Rights: The Company is obligated to file a resale registration statement covering 150% of the Conversion Shares and Warrant Shares within 30 days of the closing. Failure to do so triggers liquidated damages.
- Triggering Events: Defined events (e.g., failure to file registration statements or pay dividends) can increase the dividend rate to 15% and allow holders to demand cash redemption at a premium.
- Anti-Dilution Provisions: Both the Preferred Stock conversion price and Warrant exercise price are subject to "full ratchet" adjustments if the Company issues equity at a price below $8.00.
Investor Verification Checklist
- Verify the closing date of the Private Placement (expected October 15, 2025) and confirmation of the $11.0 million gross proceeds.
- Review the Certificate of Designations (Exhibit 3.1) for specific definitions of "Triggering Events" and redemption premiums.
- Monitor the Company's ability to file the required resale registration statement within the 30-day window to avoid liquidated damages.
- Confirm the timeline and outcome of the stockholder vote required by December 31, 2025, for Nasdaq compliance.
- Assess the impact of the "full ratchet" anti-dilution provisions on future fundraising capabilities.